AbbVie/Roche seek first-line CLL use for Venclexta comboAbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share XAbbVie/Roche seek first-line CLL use for Venclexta combohttps://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
AbbVie, Roche eye first-line use of Venclexta in leukaemiaAbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into Share XAbbVie, Roche eye first-line use of Venclexta in leukaemiahttps://pharmaphorum.com/news/abbvie-roche-venclexta-leukaemia/
AbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patientsAbbVie/Roche’s Venclexta (venetoclax) has produced a high overall response rate in chronic lymphocytic leukaemia patients with the 17p deletion mutation, Share XAbbVie/Roche’s Venclexta produces complete remission in 10% of hard-to-treat CLL patientshttps://pharmaphorum.com/transversal-categories/clinical/abbvie-roche-s-potential-blockbuster-venclexta-boosted-by-phase-ii-cll-results/
